Member Info for EmeraldCarrots

Doc3.

"Is this real? Surely a desperate action?"

=======================================

https://x.com/Parsortix/status/1988943641801531818?s=20

=======================================

Doc3.

The price for the Parsortix machines (2 types) was between I think $60k and about $70K each.

The one time use cassettes needed for every blood sample was about $300 each.

Promoting machines is normal by advertising price drops, is it not?

If I were one of the about 200 using Companies I hope I would be aware of the situation and the fact that these machines are unique in the entire World. You cant just switch supplier. I think I would be stocking up on cassettes big time (a couple of years worth?) and evaluating if buying a couple of machines for future use might be worth doing.

All IMHO.

That Government was satisfied with the data and tests carried out already. Therefore the installations don't need the staff to get all the other "paperwork" done each time a test is done. No lab test to double check the results. I think the market does not appreciate these installations should be a lot faster and easier than the ones for the UK's NHS. Once the hospital gives the green light it should be just a matter of a few weeks, tops. About another 14 installations.

Total installations for the MT-RNR1 should hit 30 IMHO within 3 or 4 months.

All IMHO.

One of the approximately 15 neonatal hospitals in Scotland should already be on board as per the old RNS. So where are we with the next 14 ish? Installation can't be more than 2 people 1 day. It's not difficult. With permission 5 hospitals per week could be added, surely?

Once there are 30 hospitals on board in total the cash burn should be minimal. There is momentum here at last. If I worked for GDR I would be interested in getting say 30% of my wages in shares for say 3 months. That would see them through and the sp should rocket.

All IMHO.

1. Immatics Inc. 3 cancer drug trials using Parsortix, one in phase 3 and one in phase 2.

2. Myriad Genetics. May use the Parsortix machine to add CTC analysis to their existing solid tumor analysis.

3. The UK's NHS. Potential Government sponsorship of "dual analysis" based on the Illumina lung cancer assay developed for Parsortix.

4. Illumina web site moving to covering "dual analysis", where Parsortix is the only proven way to date.

All IMHO.

Ima402 cancer drug candidates?

Https://investors.immatics.com/news-releases/news-release-details/immatics-achieves-clinical-proof-concept-its-next-generation-tcr

AI Overview

Yes, the Parsortix system could potentially help in identifying and monitoring patients suitable for IMA402 treatment and in the discovery of new cancer drug candidates by providing intact circulating tumor cells (CTCs) for detailed analysis.

How Parsortix can help

The Parsortix system is a liquid biopsy platform that captures and harvests intact CTCs from a simple blood draw based on their physical properties (size and deformability), independent of surface markers like EpCAM. This provides several benefits relevant to drugs like IMA402:

Patient Monitoring: The system can be used for the longitudinal monitoring of cancer patients during treatment, which helps in understanding how a patient's cancer is responding to the drug in real-time.

Biomarker Analysis: Harvested CTCs allow for various downstream analyses, including DNA, RNA, and protein analysis, to identify actionable mutations and biomarkers. This can help confirm if the PRAME target for IMA402 is present in a patient's cancer cells and whether it changes during treatment.

Identifying Resistance Mechanisms: Parsortix can help identify the mechanisms by which a tumor becomes resistant to a specific therapy (clonal evolution) by analyzing the changing genetic and proteomic profiles of CTCs over time. This information can guide subsequent treatment decisions or the development of new drug candidates to overcome resistance.

Drug Discovery and Development: By providing viable, intact CTCs, the technology enables researchers to culture these cells outside the body, allowing for the direct testing of new drugs on patient-derived cells, which could aid in the discovery of future drug candidates.

Complementary Information: Parsortix-harvested CTCs provide information complementary to other liquid biopsy methods like circulating tumor DNA (ctDNA) analysis, offering a more comprehensive picture of tumor heterogeneity.

Immatics IMA402 Context

Immatics' IMA402 is an "off-the-shelf" bispecific T cell-engaging receptor (TCER®) that targets an HLA-A*02-presented peptide derived from the protein PRAME, which is frequently expressed in various solid cancers. The goal is to redirect a patient's own T cells to attack cancer cells expressing this target.

While Immatics uses its proprietary XPRESIDENT® platform for initial target discovery, the Parsortix system could serve a complementary role in a clinical setting by providing a non-invasive way to select and monitor patients, and investigate the presence or absence of the PRAME target and associated biomarkers in real time as the disease evolves.

Ima402 cancer drug candidates?

AI Overview

Yes, the Parsortix system could potentially help in identifying and monitoring patients suitable for IMA402 treatment and in the discovery of new cancer drug candidates by providing intact circulating tumor cells (CTCs) for detailed analysis.

How Parsortix can help

The Parsortix system is a liquid biopsy platform that captures and harvests intact CTCs from a simple blood draw based on their physical properties (size and deformability), independent of surface markers like EpCAM. This provides several benefits relevant to drugs like IMA402:

Patient Monitoring: The system can be used for the longitudinal monitoring of cancer patients during treatment, which helps in understanding how a patient's cancer is responding to the drug in real-time.

Biomarker Analysis: Harvested CTCs allow for various downstream analyses, including DNA, RNA, and protein analysis, to identify actionable mutations and biomarkers. This can help confirm if the PRAME target for IMA402 is present in a patient's cancer cells and whether it changes during treatment.

Identifying Resistance Mechanisms: Parsortix can help identify the mechanisms by which a tumor becomes resistant to a specific therapy (clonal evolution) by analyzing the changing genetic and proteomic profiles of CTCs over time. This information can guide subsequent treatment decisions or the development of new drug candidates to overcome resistance.

Drug Discovery and Development: By providing viable, intact CTCs, the technology enables researchers to culture these cells outside the body, allowing for the direct testing of new drugs on patient-derived cells, which could aid in the discovery of future drug candidates.

Complementary Information: Parsortix-harvested CTCs provide information complementary to other liquid biopsy methods like circulating tumor DNA (ctDNA) analysis, offering a more comprehensive picture of tumor heterogeneity.

Immatics IMA402 Context

Immatics' IMA402 is an "off-the-shelf" bispecific T cell-engaging receptor (TCER®) that targets an HLA-A*02-presented peptide derived from the protein PRAME, which is frequently expressed in various solid cancers. The goal is to redirect a patient's own T cells to attack cancer cells expressing this target.

While Immatics uses its proprietary XPRESIDENT® platform for initial target discovery, the Parsortix system could serve a complementary role in a clinical setting by providing a non-invasive way to select and monitor patients, and investigate the presence or absence of the PRAME target and associated biomarkers in real time as the disease evolves.

Https://investors.immatics.com/news-releases/news-release-details/immatics-achieves-clinical-proof-concept-its-next-generation-tcr

Selection for Immatics Inc. Anzu-cel(IMA203) cell therapy:-

"can the expression of the PRAME peptide be measured in cells caught by parsortix?".

AI Overview

Yes, the expression of the PRAME gene (mRNA) can be measured in cells captured by the Parsortix system through downstream molecular analysis like quantitative reverse-transcriptase real-time PCR (qRT-PCR) or RNA sequencing. The Parsortix system isolates cells based on size and deformability, and the harvested cells are viable for subsequent user-validated analyses, including molecular profiling.

The expression of the PRAME peptide (protein) can also likely be measured using methods such as immunofluorescence (IF) or immunohistochemistry (IHC) on the captured cells, as these techniques have been successfully used with Parsortix-isolated cells for other biomarkers like EpCAM, CK, and Vimentin.

The key points are:

The Parsortix system is designed to capture and harvest intact, viable circulating tumor cells (CTCs) that are suitable for various downstream analyses.

Published studies have demonstrated the feasibility of performing gene expression analysis (mRNA) and protein expression analysis (using immunofluorescence/cytology) on cells captured by the system.

Specific studies have used Parsortix to obtain cells for gene expression analysis of melanoma-associated genes, showing it is a suitable platform for this kind of transcriptomic analysis.

The PRAME protein is expressed intracellularly (in the cytoplasm), though an extracellular epitope has been identified, meaning appropriate cell processing (e.g., fixation and permeabilization for intracellular staining) would be required for accurate detection.

Therefore, given the established compatibility of the Parsortix system with both molecular (RNA) and protein (IF/IHC) analysis methods, measuring PRAME expression in the captured cells is technically feasible with user-validated protocols.

cell to reprogram the t cells?

ai

to reprogram t cells effectively, immatics needs specific information about the cancer cell's surface and intracellular composition, primarily concerning the peptide antigens it presents and the patient's hla (human leukocyte antigen) type.

the key information points are:

identification of the cancer target: immatics uses its proprietary xpresident® platform to identify specific "true" cancer targets, which are peptide fragments (peptidomes) derived from intracellular proteins that are presented on the cancer cell surface by hla molecules. these targets must be:

cancer-specific or highly overexpressed: the target must be present on the tumor cells at significant levels but have minimal or no expression on healthy, normal tissues to avoid on-target off-tumor toxicity.

naturally expressed: the target needs to be naturally processed and presented by the tumor cell's hla machinery at physiological levels.

****geneously expressed: the target should be consistently present across the entire tumor to ensure the t cells can attack all cancer cells effectively.

hla type of the patient: t-cell receptors (tcrs) recognize antigens only when they are bound to a specific type of hla molecule. therefore, the patient's specific hla type (e.g., hla-a*02:01, a common type for several programs like ima203 and ima402) is required to ensure that the engineered tcr will be able to recognize the target presented on the patient's tumor cells.

target expression level: quantitative mass spectrometry is used to determine the copy number of the target peptide-hla (phla) complex on the tumor cell surface, which helps select highly potent tcrs that are effective even at low target expression levels.

tcr affinity and specificity: immatics identifies and engineers the specific t cell receptor (tcr) (using its xceptor® platform) that can bind to the identified phla complex with high affinity and specificity. this ensures a robust and precise anti-tumor attack without harming healthy tissues.

by knowing these details, immatics can select or develop the "right" tcr to engineer into a patient's (autologous) or a healthy donor's (allogeneic) t cells, effectively "reprogramming" them to specifically recognize and kill the cancerous cells.

======================================================================

it seems to me immatics inc. are using the live, intact, uncontaminated circulating tumor cells cellbxheath's parsortix machine can catch from a standard blood sample to get the information about the cancer cells to enable the "t" cells to be "reprogrammed". if so using parsortix is vital as no other machine can do this as efficiently, or maybe even at all. also why did they select parsortix?????????????

AI Overview

Immatics "reprograms" T cells by using lentiviral vectors to genetically engineer a patient's own (autologous) T cells to express a novel, proprietary T cell receptor (TCR) that is highly specific to a cancer target identified by their XPRESIDENT® platform.

The process, part of their ACTengine® approach, involves the following key steps:

Target Identification: Immatics uses its XPRESIDENT® platform to discover and validate tumor-associated peptides (TUMAPs) that are present on the surface of cancer cells (presented by HLA molecules) but largely absent on healthy tissues.

TCR Discovery: Using the XCEPTOR® platform, they identify and select a corresponding high-affinity and highly specific T cell receptor (TCR) from natural human T-cell repertoires that can recognize the identified target.

Cell Collection: A patient's own T cells are collected from their blood through a process called apheresis.

Genetic Engineering: In a specialized lab, the collected T cells are genetically modified (transduced) using a lentiviral vector to express the novel, cancer-target-specific TCR. This "reprograms" the T cells to specifically recognize the cancer.

Cell Expansion: The engineered T cells are then expanded in vitro (grown in the lab) to generate a sufficient number of cancer-fighting cells, typically billions.

Infusion: Before the engineered T cells are infused back into the patient, the patient undergoes lymphodepletion chemotherapy to prepare their body and make room for the new cells to engraft and expand.

Activation: Once reinfused, these "armed" T cells can specifically bind to tumor cells presenting the target, leading to their activation and subsequent destruction of the cancer cells.

=========================================

***"Target Identification: Immatics uses its XPRESIDENT® platform to discover and validate tumor-associated peptides (TUMAPs) that are present on the surface of cancer cells (presented by HLA molecules) but largely absent on healthy tissues.".***

Is Parsortix vital or not????????????????????

Whole Pharma industry ignore CLBX, now with a market cap of just £6m. They need to wake up and look at the proven facts. The only Plc that has/is doing their "job" checking out CLBX is Myriad Genetics. Has no-one noticed that Immatics Inc., with a valuation of $1.1 billion are using Parsortix in 3 of their cancer drug trials? One of these is in phase 3! So, what if Parsortix is vital for them to get the information from the circulation tumor cells to enable them to re-program the "T" cells before re-infusion? If this is the case and Anzu-cel(IMA203) cell therapy is passed for use, then Parsortix will be worth millions. And if this drug works more will follow using a similar technique. Maybe I have lost my mind, or maybe the market is asleep to this totally.

All IMHO.

Due to come on line in Scotland. In fact 1 should already be up and running. Maybe as it looks increasingly like they will get over the line they will consider offering shares instead of say 25% of pay to all the staff? The staff there should be increasingly confident things will work out and those shares could potentially be woth a fortune in the future.

All IMHO.

A.I. "Immatics and Parsortix".

AI Overview

Immatics has an ongoing services agreement with the biopharma company Angle PLC, where Angle provides

circulating tumor cell (CTC) enrichment services to Immatics across three of its clinical trials using the Parsortix® system.

This relationship involves:

Technology Use: Immatics utilizes the Parsortix system, developed by Angle PLC, to isolate intact, viable CTCs from patient blood samples. The Parsortix system uses a unique, label-free, size and deformability-based microfluidic technology that does not depend on specific surface markers (like EpCAM), enabling the capture of a wider range of cancer cells, including those that have undergone epithelial-to-mesenchymal transition (EMT).

Clinical Trials Support: Angle is supporting Immatics in three cancer drug trials, including a Phase 3 study in melanoma.

Purpose: The captured CTCs are used for advanced analysis (e.g., molecular profiling, genomic and transcriptomic analysis) in Immatics' cancer research and clinical development efforts, likely to evaluate patient response to its immunotherapies and to help inform treatment decisions.

In essence, Parsortix's technology serves as a crucial tool for Immatics' liquid biopsy analysis in its development of T-cell redirecting cancer immunotherapies.

==============================================

In essence, ****Parsortix's technology serves as a crucial tool for Immatics' liquid biopsy analysis****.

What do Immatics do if parsortix in no more?? Brown trousers time?

All IMHO.

Immatics have 3 cancer drug trials which use Parsortix in some way, as already confirmed. One is already at phase 3, and another has recently moved up to phase 2. The question is how vital is Parsortix in this? I don't know, but if information obtained from the live, intact, uncontaminated CTC's that Parsortix catches is vital to the re-programming of the "T-cells" Immatics would be in deep trouble if Parsortix was unavailable. Conceivably it could mean Immatics could not move on from phase 3 to actual medical use at all. That would be devastating for Immatics! I wonder? If this is the case they would have to do something..............?

========================

Immatics market cap is $1.1 Billion, Cellbxhealth is £6 million. As I keep saying, this situation is utterly ridiculous. "The market" has got is all wrong.

All IMHO.

Immatics have 3 cancer drug trials which use Parsortix in some way, as already confirmed. One is already at phase 3, and another has recently moved up to phase 2. The question is how vital is Parsortix in this? I don't know, but if information obtained from the live, intact, uncontaminated CTC's that Parsortix catches is vital to the re-programming of the "T-cells" Immatics would be in deep trouble if Parsortix was unavailable. Conceivably it could mean Immatics could not move on from phase 3 to actual medical use at all. That would be devastating for Immatics! I wonder? If this is the case they would have to do something..............?

All IMHO.

The World renowned Illumina inc., no less has effectively confirmed dual analysis (Std blood CtDna analysis plus CTC Dna analysis of the same tube of blood) works. They worked with Cellbxhealth (then called Angle Plc) to create the assay that does this for heavens sake. The services side of Cellbxhealth offers a dual analysis service for lung cancer ***at the moment***, and has done for 3 or 4 months.

Does anyone suspect the major pharma Companies have colluded against Angle Plc? It has certainly crossed my mind. I mean how on Earth, I say again HOW ON EARTH did Angle plc manage to land so few contracts bearing in mind what they can offer? It is completely ridiculous. I mean were the sales team working for or against Angle Plc! Sounds mad but it simply does NOT add up. Something is VERY VERY wrong. As far as I am concerned unless it was the old directors that ruined potential deals (Andrew Newland and Ian Griffiths) Brett Swansiger and anyone else who were involved in sales should be shown the door. I am surprised they seem to still be there. I suppose with their track record at Angle they would struggle to get a sales job anywhere else.

All IMHO...

"Illumina and ANGLE (now called Cellbxhealth) have a collaborative relationship focused on optimizing a workflow that combines the Parsortix system for capturing and harvesting circulating tumor cells (CTCs) with Illumina's Next-Generation Sequencing (NGS) instruments and assays. The goal of this collaboration is to enable Illumina's customers (e.g., pharmaceutical companies and research centers) to perform comprehensive liquid biopsy analysis, specifically the dual analysis of CTC-DNA and cell-free DNA (ctDNA)."

==================

I think the Illumina collaboration regarding "dual analysis" will snowball once the Illumina assay available for lung cancer starts being used in the World. It has only been available for about 4 months. We are talking the entire World here, and Cellbxhealth are the only Company that has this service. Illumina's updated documentation I believe World wide is slowly revealing that Parsortix is needed for dual analysis. For another Company to compete they would need to be able to catch intact uncontaminated CTC's to analyse. The Parsortix machine is the only viable one for this in existence as far as I am aware. The sp in no way represents the value of the Company. What if numerous Plc's start to use parsortix in their cancer drug trials, like Immatics already do?? Potentially hundreds of millions of dollars.

All IMHO.

=====================================

"Targeted Liquid Biopsy Panels - New targeted NGS Panel Options

Illumina

https://emea.illumina.com › lbx-panels › liquid-biopsy

Explore targeted liquid biopsy panels for your oncology research with Pillar oncoReveal. Discover new Pillar oncoReveal liquid biopsy panels on...

Liquid biopsy NGS Panels

Streamlined Oncology Workflow

Explore our portfolio

See SLIMamp Workflow"

====================================

I'm sure this was not the case a few weeks back.

Something has changed enabling "parsortix" to appear.

I guess it's Illumina's documentation finally being updated after the collaboration on "dual analysis" with parsortix, I presume, somewhere being mentioned in the documentation. So far it was amazing how Illumina managed NOT to mention Parsortix IMHO!!!!!!!!!

Cellbxhealth as far as I know are the only Company in the World that can offer lung cancer "dual analysis", and what is more ***other cancer types will follow***. One wonders if Illumina have more plans than we think for "dual analysis", something you need perfect CTC samples for which the parsortix is the best machine in the Word for....................................!!

All IMHO.

The World renowned Illumina inc., no less has effectively confirmed dual analysis (Std blood CtDna analysis plus CTC Dna analysis of the same tube of blood) works. They worked with Cellbxhealth (then called Angle Plc) to create the assay that does this for heavens sake. The services side of Cellbxhealth offers a dual analysis service for lung cancer ***at the moment***, and has done for 3 or 4 months.

Does anyone suspect the major pharma Companies have colluded against Angle Plc? It has certainly crossed my mind. I mean how on Earth, I say again HOW ON EARTH did Angle plc manage to land so few contracts bearing in mind what they can offer? It is completely ridiculous. I mean were the sales team working for or against Angle Plc! Sounds mad but it simply does NOT add up. Something is VERY VERY wrong. As far as I am concerned unless it was the old directors that ruined potential deals (Andrew Newland and Ian Griffiths) Brett Swansiger and anyone else who were involved in sales should be shown the door. I am surprised they seem to still be there. I suppose with their track record at Angle they would struggle to get a sales job anywhere else.

All IMHO.

It using Parsortix and send the result sample on to a Company with the Roche BenchMark ULTRA automated staining system and within a few hours? you find out if the sample has got cancer biomarkers that can be targeted. So we have a way of processing industrial amounts of blood samples to see what biomarkers they have. You would need a lot of Parsortix machines........... Hmmmmmmmmmmm......!!!!

All IMHO.